ElucidBoston-based firm eHealth, which develops non-invasive medical software that characterizes cardiovascular disease, has raised $27M in Series A funding.
The round was led and participated by an unidentified strategic investor. Other investors included Biovision Ventures, IAG Capital and Bold Brain Ventures.
The funds will be used by the company to increase its growth and to support its development efforts.
Elucid, headed by Blake Richards, is a medical tech company that uses interpretable and validated AI to give physicians a platform to help them make better decisions about patients with heart disease. The FDA-Cleared and CE-marked non-invasive software quantifies atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core.
The machine learning algorithms can be used to characterize the tissue types found in the artery walls that are known to cause heart attacks. New applications that are able to detect complex plaque biology at the molecular, cellular, and cellular level can derive fractional flows reserve (FFRct), risk for heart attack/stroke, expression prediction, and therapeutic selection.
This method allows physicians to diagnose chest pain and determine if patients have advanced-stage heart disease.
The software is available for commercial use in the U.S., Europe, and South Korea.